Background: Dopamine has been used in patients with cardiac dysfunction for more than five decades. Yet, no systematic review has assessed the effects of dopamine in critically ill patients with cardiac dysfunction.
and β-adrenergic receptors. 1 Low-dose dopamine (<4 µg·kg −1 ·min −1 ) is hypothesised to primarily provide mesenteric and renal arteriole vasodilation, moderate-dose dopamine (4-10 µg·kg −1 ·min −1 ) is hypothesised to have particularly positive inotropic and chronotropic effects, and high-dose dopamine (>10 µg·kg −1 ·min −1 ) is considered a vasopressor due to the increase of systemic vascular resistance. 1, 2 These doses are arbitrary as there is a wide interindividual variability of dopamine receptor sensitivity. 2 Guidelines for treatment of heart failure mention dopamine among other drugs to treat acute heart failure. 3, 4 Several randomised clinical trials (RCTs) have failed to show clinical benefits associated with use of dopamine in patients with acute heart failure [5] [6] [7] and circulatory shock. 8 Previous meta-analyses advocate cautious use of high-dose dopamine. 9 Despite the decline in its use, dopamine is still the used inotrope in 25% of acute heart failure patients and in 14% of the patients undergoing cardiac surgery. 10, 11 The debate about the benefits and harms of dopamine in critically ill patients with cardiac dysfunction remains. 11, 12 Our objective was to conduct a systematic review with meta-analyses and Trial Sequential Analyses (TSA) of RCTs comparing the benefits and harms of dopamine compared to placebo, no intervention, or any potentially active comparator in critically ill patients with cardiac dysfunction.
| METHOD S
This systematic review was conducted following our published protocol (CRD42016042867), 13 
the recommendations of The Cochrane
Handbook for Systematic Reviews of Interventions, 14 The Cochrane Hepato-Biliary Group Module, 15 and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 16 
| Eligibility criteria
We considered all RCTs eligible for inclusion irrespective of language, blinding, publication status, sample size, or control intervention(s) for assessment of benefits and harms. Quasi-randomised and observational studies were included for assessment of potential harms and results were analysed separately.
Only RCTs with critically ill adult patients with cardiac dysfunction were included in our main analysis. Critical illness encompassed any clinical setting wherein patients with objectively measured cardiac dysfunction seemed to require intravenous dopamine without restrictions on dose or duration of administration. Cardiac dysfunction was defined as a left ventricular ejection fraction (LVEF) below 45% and/or a low cardiac output syndrome. Low cardiac output syndrome was defined as a pre-existing or developing state of cardiac insufficiency with underlying left-or right-ventricular systolic dysfunction seemed to require inotrope support to maintain a systolic blood pressure >90 mm Hg and a cardiac index >2.2 L·min −1 ·m −2 . 17 RCTs including both patients with and without cardiac dysfunction were included in the review only if the majority (more than 50%) of the included patients had cardiac dysfunction. During the selection process, we had to exclude a substantial number of trials because not all trials objectively measured cardiac dysfunction for each patient. We realised that our eligibility criteria may not reflect all the situations in which doctors decide to administer dopamine. To increase the external validity of our systematic review, we conducted a post hoc analysis including trials in which a substantial proportion of patients (more than 25%) were assumed to have cardiac dysfunction.
| Outcomes
The primary outcome was all-cause mortality. The secondary outcomes were serious adverse events (SAEs), myocardial infarction, arrhythmias (including supra-and ventricular tachycardia and fibrillation), and renal failure requiring renal replacement therapy. SAEs were defined according to the International Conference on Harmonisation of Good Clinical Practice definitions, excluding mortality to avoid double counts. 18 Myocardial infarction, arrhythmias, and renal replacement therapy were defined according to the criteria used in the individual trials. We included data at longest follow-up.
| Search methods
We used a sensitive search strategy that was likely to include all clinical settings wherein cardiac dysfunction was prevalent: eg shock, heart failure, cardiac surgery (Appendix S1). We searched the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Web of Science, CINAHL, and Embase until 19 April 2018. We also searched the World Health Association's (WHO's) trial platform, Clin-icalTrials.gov, and FDA and EMA homepages for ongoing trials. Last, we searched the references of the selected trials and previous metaanalyses to identify further relevant trials.
| Trial selection, data extraction, and bias risk assessments
Two authors independently identified trials for inclusion and extracted study, patient and intervention characteristics, evaluated outcomes,
and risks of bias according to the domains of bias in The Cochrane
Handbook for Systematic Reviews of Interventions. 14 
Editorial Comment
This systematic review and meta-analysis shows that the evidence base for use of dopamine in critically ill adults with cardiac dysfunction is sparse with no firm evidence for benefit or harm. From this, routine use of dopamine in this population does not seem justified in this patient group. HIEMSTRA ET AL.
| 425
All data on the outcomes of all trials were assessed for the risks of systematic errors ('bias'), the risks of other design errors, and the risks of random errors. The three-dimensional Manhattan error matrix plot was used to facilitate the overview of available evidence at a glance. 19 We used a funnel plot to explore small trial bias. 14 
| Statistical methods
Results were presented as relative risks (RR), odds ratios (OR), and Peto's OR with 95% confidence interval (CI) when applicable. We used both a fixed-effect model and a random-effects model for our meta-analyses and presented both models in case of discrepancy. anticipated clinical diversity, we emphasised the results from the random-effects model as it provides the most conservative estimate of effect and/or CI. Heterogeneity was explored by inspection of forest plots and the chi-squared test with significance set at P-value of 0.10, and the quantity of heterogeneity was measured by I 2 . 20 We used TSA on all outcomes to control for the risks of random errors ("the play of chance") and adjust the thresholds for statistical significance when few data are present or when tested repeatedly, comparable to interim analyses in a single RCT. TSA calculates a diversity-adjusted required information size (RIS) which compares well to a sample size calculation for an RCT, and widens the thresholds for statistical significance before the RIS is accrued. The RIS was calculated based on an anticipated relative risk reduction (RRR) of 10% and appropriately adjusted for heterogeneity in terms of diversity (D 2 ) according to an overall type-I error of 5% and a power of 90% considering early and repetitive testing. 21 P-values less than TSA-adjusted significance levels were considered statistically significant. 21 We explain the interpretation of a TSA-graph in Figure S1 .
The concepts of TSA are explained in detail in the TSA Manual (http://www.ctu.dk/tsa) as well as in a recent overview. 21 We used the software package Review Manager 5.3.5 for the meta-analyses and the TSA program v.0.9.5.10 beta (http://www.ctu.dk/tsa) for the TSA.
| Sensitivity and subgroup analyses
All outcomes were dichotomous. We constructed best-worst and worst-best case scenarios as sensitivity analyses for participants lost to follow-up. Following our protocol, we conducted subgroup analyses to explore clinical heterogeneity according to: (a) risk of bias in trials; (b) control intervention (inactive compared to a potentially active control); (c) trials assessing a low dose (<4 µg·kg −1 ·min −1 ) compared to a moderate (4-10 µg·kg −1 ·min −1 ) or high dose (>10 µg·kg −1 ·min −1 ); (d) clinical setting (patients having cardiac surgery compared to patients not having cardiac surgery).
| GRADE assessments
We used the Grading of Recommendations Assessment, Development and Evaluations (GRADE) approach to rate and assess the quality of the body of evidence for each outcome and constructed a "Summary of findings" table. 22 3 | RESULTS
| Study selection
After screening the literature search, titles and abstracts, 341 articles out of 10 858 hits remained ( Figure 1 ). After assessment of fulltexts, 86 studies were included in our systematic review. Additional data was obtained from three studies. 5, 6, 23 The main meta-analysis included 17 RCTs with in total 1218 patients. [5] [6] [7] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Two observational studies were assessed for harmful outcomes. 23,38
| Characteristics of included trials
The characteristics of the 17 trials included in our meta-analyses are summarised in Table 1 . In-and exclusion criteria of each trial are presented in Table S1 . Nine trials had a two-arm design, seven trials consisted of three treatment arms, and one administered four different treatments. One trial was placebo-controlled, 7 The timing of administering the experimental intervention differed between the treatment arms.
had objectively verified cardiac dysfunction defined by an LVEF below 45% or a low cardiac output syndrome. 25, 27, 29, 34, 36, 37 In a sensitivity analyses we only included these seven trials; findings were comparable to the analysis of 17 trials (e- Table 2 , Appendix S2).
| Risk of bias
All 17 trials were at overall high risk of bias ( Figure 2 ). Fourteen trials were at high risk of other bias, because nine trials (53%) did not provide a statement on conflicts of interest, two trials (12%) allowed cross-over to another inotrope, and three trials (18%) were at risk of vested interests. Table 2 summarises the meta-analysed intervention effect estimates.
| Outcomes
Due to absence of trials at overall low risk of bias and also due to absence of trials administering high-dose dopamine, we were unable to conduct these predefined subgroup analyses. None of the comparisons or outcomes could be analysed with the TSA using our prespecified parameters. As a sensitivity analyses, we conducted a TSA with a type I error of 5%, type II error of 10%, and an RRR of 20% on our primary outcome mortality to evaluate the direction of the cumulative Z-curve. with an inactive control or with a potentially active control (Figure 3 ).
|
TSA on all trials showed that 19% of the RIS data was accrued and that about another 4292 patients need to become randomised in RCTs before the RIS will be reached (Figure 4 ; RR 0.91; TSA-adjusted CI 0.50-1.67). Figure S2 ). Some trials compared dopamine with both a control intervention and a potentially active control (ie three-arm design), which is why the combined number of trials in subgroup analysis 1 differ from the total amount.
| Serious adverse events

| Other outcomes
There were no significant differences in favour of any intervention on the other outcomes ( Table 2 ). None of the outcomes could be analysed with TSA using our prespecified parameters because <5%
of RIS was accrued.
| Comparison 2: trials subdivided by dopamine dose (low compared to moderate)
| All-cause mortality
Seven trials administered low-dose dopamine (ie <4 µg·kg −1 ·min −1 ) and seven trials a moderate dose (4-10 µg·kg −1 ·min −1 ). Trials that studied low-dose dopamine in patients with heart-failure targeted to increase diuresis by improving renal perfusion, whereas low-dose dopamine during cardiac surgery was used to preserve renal function. Moderate dosedopamine was administered in both patients with heart-failure and cardiac surgery patients to increase renal perfusion and ameliorate cardiac function. One trial that reported mortality did not report on the dopamine dose. 30 No statistically significant associations between different doses of dopamine and mortality were found ( Table 2 ).
| Serious adverse events
The occurrence of SAEs was recorded in three trials that administered low-dose dopamine and in four trials administering moderatedose dopamine. No significant differences were found for either low-or moderate-dose dopamine ( Table 2 ).
| Other outcomes
In the low-dose dopamine group there was significant heterogeneity 
| Comparison 3: trials subdivided by setting
(heart failure compared to cardiac surgery)
| All-cause mortality
Ten trials were conducted in patients admitted with acute heart failure and seven trials in patients undergoing cardiac surgery. Heart failure was often based on clinical symptoms classified by the New York Heart Association (NYHA) and a depressed LVEF (Table S1 ).
The type of cardiac surgery varied between the trials: two trials included patients having cardiac artery bypass grafting, 34, 36 two trials included patients having mitral valve surgery, 35, 37 and three trials included patients having various cardiac surgeries. [31] [32] [33] Subgroup analyses by clinical setting did not show any statistically significant associations on mortality ( Table 2 ).
| Serious adverse events
Serious adverse events were reported in four trials that included patients with acute heart failure and in two trials that included patients undergoing cardiac surgery. There were no statistically significant associations on occurrence of SAEs in both settings ( Table 2 ).
| Other outcomes
There was no significant difference in favour of any intervention on the proportion of myocardial infarction, renal replacement therapy, and ventricular or atrial tachyarrhythmias ( Table 2 ).
| Post hoc meta-analyses with broader inclusion criteria of cardiac dysfunction
These post hoc meta-analyses included trials in which a substantial proportion of patients (>25%) were assumed to have cardiac dysfunction. This broader inclusion criterion added ten trials with patients suffering from shock (n = 1679) or septic shock (n = 444), who received high-dose dopamine for treatment of hypotension.
This meta-analysis included 40 trials with 4182 patients and full details can be found in Appendix S2.
Dopamine seemed associated with increased mortality, increased
SAEs, and increased tachyarrhythmias when compared with a potentially active control intervention (Table S2 ). The excess mortality was trials reporting on mortality showed that it is highly unlikely to show a beneficial effect of dopamine with further trials, as the cumulative Z-curve would have to cross the futility area ( Figure S4 ).
| Observational studies
One quasi-randomised study and one observational study were assessed for harms. 23, 38 One study compared dopamine to levosimendan and recorded SAEs and arrhythmias 38 ; the other evaluated dopamine to an intra-aortic balloon pump and reported myocardial infarction and renal replacement therapy proportions. 23 Dopamine did not significantly affect any of these outcomes (Table S3 ).
| Quality of evidence
Based on GRADE, the certainty of the evidence on all outcomes was judged as 'very low' and was mainly attributable to serious risks of bias, serious indirectness, and very serious imprecision ( Table 3 ). The Manhattan error matrix plots showed that there are lacunas in the evidence of dopamine regarding both systematic errors and random errors ( Figure S5 ). The funnel plots showed no clear arguments for small trial bias including publication bias ( Figure S6 ).
| DISCUSSION
Our main meta-analysis consisting of 17 trials with 1218 patients did not provide high-quality evidence to support or refute the use of dopamine. All trials were at overall high risk of bias, only one trial compared dopamine with placebo, and TSA showed that further thousands of patients need to be randomised before firm conclusions can be drawn. The use of dopamine as preferred inotrope in up to 25% of heart failure patients lacks evidence from RCTs.
The largest trial on dopamine thus far observed that high-dose dopamine, as compared with noradrenaline, is associated with increased 28-day mortality in the subgroup of patients with cardiogenic shock. 8 We could not include these patients in our main meta-analysis because cardiac function was not measured in each patient and the randomisation procedure was not stratified for the cardiogenic shock subgroup.
The increased mortality was supported by a meta-analysis including trials randomising patients with cardiogenic shock receiving high-dose dopamine. 39 We were unable to include these trials because the metaanalysis did not elaborate on cardiac function of each trial population and the full-text manuscripts were inaccessible to us (ie the Wanfang and Weipu Database). Based on these studies, high-dose dopamine for treatment of cardiogenic shock seems associated with increased harm.
Dopamine for treatment of cardiac dysfunction also seems harmful according to observational data. 11 Nevertheless, the quality of current evidence on the possible benefits or harms of dopamine, milrinone, levosimendan, and probably all other inotropes is considered very low. 40, 41 There is currently no high-quality evidence on which There was considerable statistical heterogeneity (I 2 77%, P = 0.004), which was caused by one study at high risk of bias.
inotrope should preferentially be administered to patients with cardiac dysfunction.
Previous systematic reviews on dopamine in critically ill adult patients differ in design; all studied dopamine in patients with cardiogenic, 39, 42 hypotensive, 9 or septic shock. [43] [44] [45] [46] [47] Some identified a potentially harmful effect of dopamine on mortality and occurrence of arrhythmias, 39, 43, 44, 46 while others were inconclusive. 9, 42, 45, 47 These systematic reviews used different inclusion criteria and most studied high-dose dopamine. 9, 39, [43] [44] [45] [46] [47] The main analysis of our systematic review included fewer patients (n = 1218) compared to five of the other reviews (n = 510, 39 n = 70, 42 n = 1400, 9 n = 2043, 44 n = 1408, 43,47 n = 3819, 45 n = 1718 46 ) due to our more stringent inclusion criteria on cardiac dysfunction. We selected patients with objectively measured cardiac dysfunction because these patients would presumably benefit the most from an inotropic drug based on a pathophysiological reasoning. Critically ill patients with a normal cardiac function probably benefit less from the inotropic effects of dopamine and are more likely to only suffer potential harms. More insight is needed into the pathophysiology of shock on organ level with bridging to haemodynamic goals to achieve optimal organ function support in critically ill patients. To detect possible sources of clinical heterogeneity, we first conducted subgroup analyses on dopamine dose, clinical setting, and a sensitivity analysis of trials exclusively including patients with cardiac dysfunction. Second, we conducted post hoc meta-analyses with a broader inclusion criterion for cardiac dysfunction.
| Limitations and strengths
| CONCLUSIONS
Evidence for dopamine in critically ill adults with cardiac dysfunction is sparse and of low quality due to high risks of systematic errors and random errors. The use of dopamine in patients with cardiac dysfunction can neither be recommended nor refuted.
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